Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Gains from Sales and Divestitures (2018 - 2023)

Dianthus Therapeutics (DNTH) has 3 years of Gains from Sales and Divestitures data on record, last reported at $6495.0 in Q4 2023.

  • For Q4 2023, Gains from Sales and Divestitures fell 91.51% year-over-year to $6495.0; the TTM value through Dec 2023 reached $6495.0, down 91.51%, while the annual FY2023 figure was $6495.0, 91.51% down from the prior year.
  • Gains from Sales and Divestitures reached $6495.0 in Q4 2023 per DNTH's latest filing, up from $2989.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $76539.0 in Q4 2022 and bottomed at $2989.0 in Q3 2023.